Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13497573 | 0.92 | S1PR1 (1.00) | S1PR1CYP2C19 | |
| SCHEMBL3450719 | 0.92 | S1PR1 (1.00) | S1PR1CYP2C19 | |
| SCHEMBL3450727 | 0.92 | S1PR1 (1.00) | S1PR1CYP2C19 | |
| SCHEMBL3448572 | 0.86 | S1PR1 (0.68) | S1PR1CYP2C19CYP2D6 | |
| SCHEMBL3451470 | 0.85 | S1PR1 (0.77) | S1PR1CYP2C19CYP2D6 | |
| SCHEMBL3450067 | 0.85 | S1PR1 (0.75) | S1PR1CYP2C19CYP2D6 | |
| SCHEMBL3448905 | 0.85 | S1PR1 (0.73) | S1PR1CYP2C19CYP2D6 | |
| SCHEMBL3449368 | 0.84 | S1PR1 (0.72) | S1PR1CYP2C19CYP2D6 | |
| SCHEMBL3449459 | 0.84 | S1PR1 (0.88) | S1PR1CYP2C19CYP2D6 | |
| SCHEMBL3449814 | 0.83 | S1PR1 (0.80) | S1PR1CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| WO-2008056150-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | EDF1, ERLIN1, ECE1 | S1PR1 800/4885CYP2C19 2874/4885CYP2D6 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.